On Friday, Pacira BioSciences Inc (NASDAQ: PCRX) was -9.57% drop from the session before settling in for the closing price of $26.02. A 52-week range for PCRX has been $19.81 – $27.64.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -51.99%. When this article was written, the company’s average yearly earnings per share was at -7.66%. With a float of $41.59 million, this company’s outstanding shares have now reached $42.97 million.
Pacira BioSciences Inc (PCRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pacira BioSciences Inc stocks. The insider ownership of Pacira BioSciences Inc is 2.37%, while institutional ownership is 114.71%. The most recent insider transaction that took place on Jan 05 ’26, was worth 34,324. In this transaction Senior Vice President, Finance of this company sold 1,416 shares at a rate of $24.24, taking the stock ownership to the 59,064 shares. Before that another transaction happened on Jan 05 ’26, when Company’s Officer proposed sale 1,416 for $24.24, making the entire transaction worth $34,324.
Pacira BioSciences Inc (PCRX) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted 0.91 earnings per share (EPS) during the time that was better than consensus figure (set at 0.83) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.33% during the next five years compared to -51.99% drop over the previous five years of trading.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
You can see what Pacira BioSciences Inc (PCRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.56. Likewise, its price to free cash flow for the trailing twelve months is 9.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.45, a number that is poised to hit 0.90 in the next quarter and is forecasted to reach 3.41 in one year’s time.
